Loading organizations...
Batea Oncology is a biotechnology company developing medical device therapies for aggressive cancers, operating out of Santiago de Compostela, Spain. The startup's lead product, GlioHook, is a patented biomaterial implant placed in the surgical cavity following tumor resection to trap residual cells and increase radiotherapy sensitivity. Initially targeting glioblastoma, the enterprise integrates its non-pharmacological devices into standard neurosurgery and chemoradiotherapy protocols to reduce patient relapse risk. The early-stage firm has secured over €1.4 million in competitive grants through organizations like the Spanish Association Against Cancer, the State Innovation Agency, and IGAPE. The core technology originated as a spin-out from Nasasbiotech research conducted at the Hospital Clínico Universitario. Batea Oncology was founded in 2024 by a research team including Sonia Martínez Arca, Jorge Barbazán, Alba Ferreirós, Miguel Abal, Eladio Crego, Lorena Alonso, and Rafael López.
Batea Oncology has raised $880K across 1 funding round.
Batea Oncology has raised $880K in total across 1 funding round.
Batea Oncology has raised $880K across 1 funding round. Most recently, it raised $880K Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 15, 2025 | $880K Seed | — | Unirisco, Xesgalicia | Announced |
Batea Oncology has raised $880K in total across 1 funding round.
Batea Oncology's investors include Unirisco, Xesgalicia.
